Gamida Cell shifts focus to NiCord stem cell product
Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake...
View ArticleLeerink starts FATE Therapeutics at outperform
Leerink Partners has initiated coverage of FATE Therapeutics (NASDAQ:FATE) with an “outperform” rating and $10 price target in 12 months. The stock closed at $6.26 on Friday. FATE is focused on...
View Article
More Pages to Explore .....